ストックスクリーナーアプリを入手
0.5158
3.32%
-0.0177
アフターアワーズ：
.51
-0.0058
-1.12%
Nkgen Biotech Inc (NKGN) 最新ニュース
Nkgen Biotech Announces Administration Of First Dose Of Troculeucel To Stroke Patient Under FDA-Cleared Compassionate Use Program - Marketscreener.com
NKGen Biotech announces administration of first dose of troculeucel - TipRanks
NKGen Biotech Announces Administration of First Dose of - GlobeNewswire
Can NK Cell Therapy Help Stroke Patients? NKGen's FDA-Cleared Treatment Begins Testing - StockTitan
NKGen Biotech Doses First FTD Patient With Troculeucel Under FDA Compassionate Use - Nasdaq
NKGen Biotech Announces Administration Of First Dose Of Troculeucel To Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program - Marketscreener.com
Groundbreaking Brain Barrier-Crossing Treatment Starts in Frontotemporal Dementia PatientWill NK Cells Change Neurology? - StockTitan
NKGen Biotech Inc (NKGN) At $0.48: It’s Worth Your Interest - Stocks Register
NKGen Appoints Dr. Anita Fletcher as National Principal - GlobeNewswire
NKGen Appoints Dr. Anita Fletcher As National Principal Investigator For Phase 2A Troculeucel Trial Evaluating Moderate Alzheimer'S Disease With Adventhealth Orlando As First East Coast Site - Marketscreener.com
Can This NK Cell Therapy Transform Alzheimer's Treatment? Phase 1 Shows Remarkable 90% Success - StockTitan
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Midday Stock Roundup: RxSight Down 6.1% on Weak Post-3Q Results - Orange County Business Journal
FDA fast tracks NKGen's Alzheimer's therapy troculeucel - MSN
NKGen Biotech Announces Publication of Phase 1 Troculeucel - GlobeNewswire
Market cap of NKGen Biotech Inc [NKGN] reaches 37.83M – now what? - The DBT News
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
NKGen's Troculeucel Therapy Demonstrates Stability And Cognitive Improvement In AD Trial - Nasdaq
NKGen Biotech Announces Publication of Phase 1 Troculeucel Clinical Trial Results for the ... - The Bakersfield Californian
Revolutionary Alzheimer's Treatment Shows Remarkable 90% Success in Phase 1 Trial - StockTitan
Why AppLovin Shares Are Trading Higher By Around 29%; Here Are 20 Stocks Moving Premarket - Benzinga India
FDA Fast Track Designation Sends Biotech Soaring Mid-Week - The Globe and Mail
FDA fast tracks NKGen's Alzheimer's therapy troculeucel By Investing.com - Investing.com Australia
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
NKGen jumps on FDA's 'fast track' designation for Alzheimer's drug - TradingView
NKGen Biotech Shares Rise After FDA Grants Fast-Track Status to Alzheimer's Drug Candidate - Marketscreener.com
NKGen Biotech Receives U.S. FDA Fast Track Designation for - GlobeNewswire
Revolutionary NK Cell Therapy for Alzheimer's Disease Receives FDA Fast-Track Status - StockTitan
How to Use the Immune System Against Cancer and Alzheimer's, with Dr. Paul Song - upworthyscience.com
NKGen Biotech (NYSE:NKGN) Trading Up 9.5% – Time to Buy? - Defense World
Midday Stock Roundup: Alignment Healthcare Rises on Update - Orange County Business Journal
NKGen Biotech regains compliance with Nasdaq listing standards - Investing.com
NKGen Biotech secures $4.5M in convertible loan agreement - Investing.com India
NKGen Biotech secures $4.5M in convertible loan agreement By Investing.com - Investing.com Canada
NKGen Biotech (NYSE:NKGN) Shares Down 2.3% – Here’s Why - Defense World
Top 5 Biotech Stocks That Captured Retail Investor Interest The Most In 2024 - Asianet Newsable
NKGen Biotech Awards Stock Options to Executives - TipRanks
Head to Head Survey: HilleVax (NASDAQ:HLVX) versus NKGen Biotech (NYSE:NKGN) - Defense World
NKGen Biotech faces Nasdaq delisting over market value By Investing.com - Investing.com Canada
NKGen Biotech faces Nasdaq delisting over market value - Investing.com
NKGen Biotech Selected as Stalking Horse Bidder for NKMax - GlobeNewswire
NKGen Biotech Secures $18M Bid for NKMax Acquisition, Expanding Global IP Rights - StockTitan
NKGen Biotech selected as preferred stalking horse bidder for NKMax - Nasdaq
NKGen Biotech faces Nasdaq compliance issue By Investing.com - Investing.com Canada
NKGen Biotech faces Nasdaq compliance issue - Investing.com India
3.13%
1.23%
大文字化:
|
ボリューム (24 時間):